Status:
TERMINATED
Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to apply Whole-body DW imaging alongside the routine management of patients requiring systemic therapy for metastatic breast cancer to compare the time to progression of...
Eligibility Criteria
Inclusion
- Age over 18 years.
- First metastatic breast cancer relapse after treatment for early stage disease
- A minimum of 10 evaluable lesions in the liver on routine x-ray CT imaging
- Patient prescribed cytotoxic, endocrine or biological therapies
- Patient physically and psychologically fit enough to consider sequential WB-- - DWI imaging alongside their standard disease monitoring
- Written informed consent
Exclusion
- Diagnosis of other cancer within the last 5 years, other than resected non-melanoma skin cancer or cervical intraepithelial neoplasia
- Diagnosis of brain metastases.
- Contraindication to magnetic resonance MR imaging
Key Trial Info
Start Date :
May 11 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 23 2017
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT02257775
Start Date
May 11 2015
End Date
November 23 2017
Last Update
January 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden
Sutton, United Kingdom, SM2 5PT